Published in J Med Chem on June 25, 2009
The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle (2011) 1.77
The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors. Br J Pharmacol (2013) 1.70
Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu Rev Physiol (2010) 1.68
Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer. Cell Cycle (2009) 1.66
MicroRNAs are mediators of androgen action in prostate and muscle. PLoS One (2010) 1.01
Hormonal approaches to male contraception. Curr Opin Urol (2010) 1.01
Does ethnicity matter in male hormonal contraceptive efficacy? Asian J Androl (2011) 0.96
The role of androgens in metabolism, obesity, and diabetes in males and females. Obesity (Silver Spring) (2015) 0.90
Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Curr Oncol Rep (2016) 0.83
Therapies for musculoskeletal disease: can we treat two birds with one stone? Curr Osteoporos Rep (2014) 0.83
Androgen effects on skeletal muscle: implications for the development and management of frailty. Asian J Androl (2014) 0.83
Selective androgen receptor modulators for the treatment of late onset male hypogonadism. Asian J Androl (2014) 0.83
Anabolic effect of plant brassinosteroid. FASEB J (2011) 0.82
Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer's disease. ACS Chem Neurosci (2013) 0.82
Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem (2010) 0.82
Complex modulation of androgen responsive gene expression by methoxyacetic acid. Reprod Biol Endocrinol (2011) 0.82
Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome. Diabetes (2014) 0.81
Structural and Functional Evidence for Testosterone Activation of GPRC6A in Peripheral Tissues. Mol Endocrinol (2015) 0.81
Estrogens and Androgens in Skeletal Physiology and Pathophysiology. Physiol Rev (2017) 0.81
Structure-based virtual screening and identification of a novel androgen receptor antagonist. J Biol Chem (2012) 0.80
An update on male hypogonadism therapy. Expert Opin Pharmacother (2014) 0.80
Solution formulation development and efficacy of MJC13 in a preclinical model of castration-resistant prostate cancer. Pharm Dev Technol (2014) 0.79
Antischistosomal versus antiandrogenic properties of aryl hydantoin Ro 13-3978. Am J Trop Med Hyg (2014) 0.79
Extranuclear Actions of the Androgen Receptor Enhance Glucose-Stimulated Insulin Secretion in the Male. Cell Metab (2016) 0.79
Pharmacology of manipulating lean body mass. Clin Exp Pharmacol Physiol (2015) 0.78
Male osteoporosis and androgenic therapy: from testosterone to SARMs. Clin Cases Miner Bone Metab (2009) 0.78
Methoxychalcone inhibitors of androgen receptor translocation and function. Bioorg Med Chem Lett (2012) 0.77
The androgen receptor and its use in biological assays: looking toward effect-based testing and its applications. J Anal Toxicol (2011) 0.76
Local delivery of a selective androgen receptor modulator failed as an anabolic agent in a rat bone marrow ablation model. Acta Orthop (2015) 0.75
A Molecular Modeling Study of the Hydroxyflutamide Resistance Mechanism Induced by Androgen Receptor Mutations. Int J Mol Sci (2017) 0.75
Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation. J Comput Aided Mol Des (2016) 0.75
Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A (2005) 2.89
Status of PharmD/PhD programs in colleges of pharmacy: the University of Tennessee dual PharmD/PhD program. Am J Pharm Educ (2006) 2.35
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood (2008) 2.22
Differences between parents of young versus adult children seeking to participate in family-to-family psychoeducation. Psychiatr Serv (2014) 1.97
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol (2013) 1.78
The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle (2011) 1.77
Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther (2003) 1.73
Chemistry and structural biology of androgen receptor. Chem Rev (2005) 1.72
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood (2007) 1.69
Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol (2003) 1.65
Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J Med Chem (2004) 1.64
Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab (2006) 1.63
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma (2009) 1.58
Synthesis and antiproliferative activity of 2-aryl-4-oxo-thiazolidin-3-yl-amides for prostate cancer. Bioorg Med Chem Lett (2004) 1.57
Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med (2011) 1.57
Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem (2005) 1.54
An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res (2012) 1.49
Compound 49b prevents diabetes-induced apoptosis through increased IGFBP-3 levels. Invest Ophthalmol Vis Sci (2012) 1.46
The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. Gastroenterology (2007) 1.42
Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. J Pharmacol Exp Ther (2003) 1.41
Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J Med Chem (2005) 1.40
Nonsteroidal selective androgen receptor modulators enhance female sexual motivation. J Pharmacol Exp Ther (2010) 1.39
Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. Eur J Med Chem (2002) 1.39
PRC2 complexes with JARID2, MTF2, and esPRC2p48 in ES cells to modulate ES cell pluripotency and somatic cell reprogramming. Stem Cells (2011) 1.37
A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor. J Med Chem (2004) 1.35
Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology (2005) 1.27
Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. J Med Chem (2009) 1.27
A selective androgen receptor modulator for hormonal male contraception. J Pharmacol Exp Ther (2004) 1.25
Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst (2003) 1.25
Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol (2003) 1.25
Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3beta, 17alpha, 20-triol and their bioactivity in melanoma cells. Steroids (2008) 1.24
Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. J Med Chem (2010) 1.21
FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res (2010) 1.21
Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands. Bioorg Med Chem Lett (2005) 1.19
Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha. Biochim Biophys Acta (2007) 1.18
Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today (2007) 1.18
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.12
Novel branched poly(ethylenimine)-cholesterol water-soluble lipopolymers for gene delivery. Biomacromolecules (2002) 1.12
A comprehensive approach to faculty development. Am J Pharm Educ (2006) 1.11
Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal (2008) 1.11
The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther (2005) 1.10
Synthesis and photo-conversion of androsta- and pregna-5,7-dienes to vitamin D3-like derivatives. Photochem Photobiol Sci (2008) 1.09
Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agents. J Med Chem (2011) 1.09
Micellar delivery of bicalutamide and embelin for treating prostate cancer. Pharm Res (2009) 1.07
Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability. Drug Metab Dispos (2011) 1.04
TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol (2013) 1.03
Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Clin Cancer Res (2013) 1.03
Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis. Pharm Res (2012) 1.02
Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents. J Med Chem (2012) 1.02
Estrogen receptor-{beta}-selective ligands alleviate high-fat diet- and ovariectomy-induced obesity in mice. J Biol Chem (2010) 1.01
Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem Soc Trans (2012) 1.01
Synthesis and photochemical transformation of 3β,21-dihydroxypregna-5,7-dien-20-one to novel secosteroids that show anti-melanoma activity. Steroids (2010) 1.01
Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents. Bioorg Med Chem (2009) 1.01
MicroRNAs are mediators of androgen action in prostate and muscle. PLoS One (2010) 1.01
Proximicin A, B and C, novel aminofuran antibiotic and anticancer compounds isolated from marine strains of the actinomycete Verrucosispora. J Antibiot (Tokyo) (2008) 1.01
USP49 deubiquitinates histone H2B and regulates cotranscriptional pre-mRNA splicing. Genes Dev (2013) 1.01